Overview

First-in-Human Study of GM-60106 in Healthy Adults and Otherwise Healthy Adults With an Increased Body Mass Index and Markers of Non-Alcoholic Fatty Liver Disease

Status:
Enrolling by invitation

Trial end date:
2023-06-30

Target enrollment:

Participant gender:

Summary

This is a Phase 1a/1b, randomised, double-blind, placebo-controlled single- and multiple-ascending dose study to evaluate the safety, tolerability, PK, and PD of GM-60106 in healthy adult male and female participants and otherwise healthy adults who have an increased BMI and markers of NAFLD.

Phase:

Phase 1

Details

Lead Sponsor:

JD Bioscience Inc.

Collaborator:

Novotech (Australia) Pty Limited